SCHEMBL2970271

SCHEMBL2970271

Cc1coc(-c2ccc3c(c2-c2occ(C)c2C)[CH]c2ccccc2-3)c1C

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.34
KDM1A O60341 1/20 0.34
EED O75530 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
CES1 P23141 1/20 0.34
PTPN6 P29350 1/20 0.34
BLM P54132 1/20 0.34
PTPN11 Q06124 1/20 0.34
SUZ12 Q15022 1/20 0.34
EZH2 Q15910 1/20 0.34
HIF1A Q16665 1/20 0.34
NSD1 Q96L73 1/20 0.34
EPAS1 Q99814 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
IDO1 P14902 1/20 0.33
TDO2 P48775 1/20 0.33
NQO1 P15559 2/20 0.31
POR P16435 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2965810 0.86 CES2 (0.31) CES2KDM1AEEDPOLBMAPT
SCHEMBL2970092 0.78 ADRA1D (0.34)
SCHEMBL2973122 0.72
SCHEMBL2966274 0.71 ALDH1A1 (0.33) POLBMAPTCES1IDO1NQO1
SCHEMBL218438 0.70 TSHR (0.34) POLBMAPTTDP1
SCHEMBL217878 0.68 ALDH1A1 (0.36) MAPTTDO2
SCHEMBL216981 0.66 ACHE (0.39) TDP1
SCHEMBL2973118 0.66
SCHEMBL2968620 0.66 ADRA1D (0.39) NQO1POR
SCHEMBL2965734 0.65 PTGS2 (0.36) POLBMAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7276567-B2 Heterocyclic substituted metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. (US) 2007-10-02 US claimed
US-7763562-B2 Heteroatom bridged metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. (US) 2010-07-27 US disclosed
US-7276567-B2 Heterocyclic substituted metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. (US) 2007-10-02 US disclosed
US-20070135597-A1 Heteroatom bridged metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. 2007-06-14 US disclosed
US-7214747-B2 Phosphorus substituted metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. (US) 2007-05-08 US disclosed
US-7214746-B2 Phosphorus bridged metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. (US) 2007-05-08 US disclosed
US-20050261449-A1 Heterocyclic substituted metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENT INC. 2005-11-24 US disclosed
US-20050239981-A1 Phosphorus bridged metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. 2005-10-27 US disclosed
US-20050239980-A1 Phosphorus substituted metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. 2005-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239981-A1 Phosphorus bridged metallocene compounds for olefin polymerization PYM1, ZNF207, POLL CES2 4308/4885KDM1A 2981/4885EED 302/4885
US-20070135597-A1 Heteroatom bridged metallocene compounds for olefin polymerization AP2M1, AP1M1, PYM1 CES2 4242/4885KDM1A 3280/4885EED 1009/4885
US-20050239980-A1 Phosphorus substituted metallocene compounds for olefin polymerization CCRL2, ARL1, OSBP2 CES2 2758/4885KDM1A 4352/4885EED 1251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.